PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis

Cristian Rodriguez-Aguayo, Emine Bayraktar, Cristina Ivan, Burcu Aslan, Junhua Mai, Guangan He, Lingegowda Selanere Mangala, Dahai Jiang, Archana S. Nagaraja, Bulent Ozpolat, Arturo Chavez-Reyes, Mauro Ferrari, Rahul Mitra, Zahid H Siddik, Haifa Shen, Xianbin Yang, Anil K Sood, Gabriel Lopez

Research output: Contribution to journalArticle

Abstract

Background: Inflammatory mediator prostaglandin E2–prostaglandin E2 receptor EP3 (PTGER3) signaling is critical for tumor-associated angiogenesis, tumor growth, and chemoresistance. However, the mechanism underlying these effects in ovarian cancer is not known. Methods: An association between higher tumoral expression of PTGER3 and shorter patient survival in the ovarian cancer dataset of The Cancer Genome Atlas prompted investigation of the antitumor effects of PTGER3 downmodulation. PTGER3 mRNA and protein levels were higher in cisplatin-resistant ovarian cancer cells than in their cisplatin-sensitive counterparts. Findings: Silencing of PTGER3 via siRNA in cancer cells was associated with decreased cell growth and less invasiveness, as well as cell-cycle arrest and increased apoptosis, mediated through the Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. Furthermore, sustained PTGER3 silencing with multistage vector and liposomal 2’-F-phosphorodithioate-siRNA–mediated silencing of PTGER3 combined with cisplatin resulted in robust antitumor effects in cisplatin-resistant ovarian cancer models. Interpretation: These findings identify PTGER3 as a potential therapeutic target in chemoresistant ovarian cancers expressing high levels of this oncogenic protein. Fund: National Institutes of Health/National Cancer Institute, USA.

Original languageEnglish (US)
Pages (from-to)290-304
Number of pages15
JournalEBioMedicine
Volume40
DOIs
StatePublished - Feb 1 2019

Fingerprint

Dinoprostone
Cisplatin
Ovary
Carcinogenesis
Up-Regulation
Ovarian Neoplasms
Cells
Therapeutics
Tumors
Neoplasms
National Cancer Institute (U.S.)
Atlases
National Institutes of Health (U.S.)
Cell growth
Growth
Cell Cycle Checkpoints
Small Interfering RNA
Proteins
Genes
Health

Keywords

  • CFTR
  • Chemically modified siRNA
  • Cisplatin resistance
  • ELK1
  • ETS1
  • Ovarian cancer
  • PTGER3
  • RNA interference

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. / Rodriguez-Aguayo, Cristian; Bayraktar, Emine; Ivan, Cristina; Aslan, Burcu; Mai, Junhua; He, Guangan; Mangala, Lingegowda Selanere; Jiang, Dahai; Nagaraja, Archana S.; Ozpolat, Bulent; Chavez-Reyes, Arturo; Ferrari, Mauro; Mitra, Rahul; Siddik, Zahid H; Shen, Haifa; Yang, Xianbin; Sood, Anil K; Lopez, Gabriel.

In: EBioMedicine, Vol. 40, 01.02.2019, p. 290-304.

Research output: Contribution to journalArticle

@article{30a59c2529c44b46bb57d76960196376,
title = "PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis",
abstract = "Background: Inflammatory mediator prostaglandin E2–prostaglandin E2 receptor EP3 (PTGER3) signaling is critical for tumor-associated angiogenesis, tumor growth, and chemoresistance. However, the mechanism underlying these effects in ovarian cancer is not known. Methods: An association between higher tumoral expression of PTGER3 and shorter patient survival in the ovarian cancer dataset of The Cancer Genome Atlas prompted investigation of the antitumor effects of PTGER3 downmodulation. PTGER3 mRNA and protein levels were higher in cisplatin-resistant ovarian cancer cells than in their cisplatin-sensitive counterparts. Findings: Silencing of PTGER3 via siRNA in cancer cells was associated with decreased cell growth and less invasiveness, as well as cell-cycle arrest and increased apoptosis, mediated through the Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. Furthermore, sustained PTGER3 silencing with multistage vector and liposomal 2’-F-phosphorodithioate-siRNA–mediated silencing of PTGER3 combined with cisplatin resulted in robust antitumor effects in cisplatin-resistant ovarian cancer models. Interpretation: These findings identify PTGER3 as a potential therapeutic target in chemoresistant ovarian cancers expressing high levels of this oncogenic protein. Fund: National Institutes of Health/National Cancer Institute, USA.",
keywords = "CFTR, Chemically modified siRNA, Cisplatin resistance, ELK1, ETS1, Ovarian cancer, PTGER3, RNA interference",
author = "Cristian Rodriguez-Aguayo and Emine Bayraktar and Cristina Ivan and Burcu Aslan and Junhua Mai and Guangan He and Mangala, {Lingegowda Selanere} and Dahai Jiang and Nagaraja, {Archana S.} and Bulent Ozpolat and Arturo Chavez-Reyes and Mauro Ferrari and Rahul Mitra and Siddik, {Zahid H} and Haifa Shen and Xianbin Yang and Sood, {Anil K} and Gabriel Lopez",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.ebiom.2018.11.045",
language = "English (US)",
volume = "40",
pages = "290--304",
journal = "EBioMedicine",
issn = "2352-3964",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis

AU - Rodriguez-Aguayo, Cristian

AU - Bayraktar, Emine

AU - Ivan, Cristina

AU - Aslan, Burcu

AU - Mai, Junhua

AU - He, Guangan

AU - Mangala, Lingegowda Selanere

AU - Jiang, Dahai

AU - Nagaraja, Archana S.

AU - Ozpolat, Bulent

AU - Chavez-Reyes, Arturo

AU - Ferrari, Mauro

AU - Mitra, Rahul

AU - Siddik, Zahid H

AU - Shen, Haifa

AU - Yang, Xianbin

AU - Sood, Anil K

AU - Lopez, Gabriel

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Background: Inflammatory mediator prostaglandin E2–prostaglandin E2 receptor EP3 (PTGER3) signaling is critical for tumor-associated angiogenesis, tumor growth, and chemoresistance. However, the mechanism underlying these effects in ovarian cancer is not known. Methods: An association between higher tumoral expression of PTGER3 and shorter patient survival in the ovarian cancer dataset of The Cancer Genome Atlas prompted investigation of the antitumor effects of PTGER3 downmodulation. PTGER3 mRNA and protein levels were higher in cisplatin-resistant ovarian cancer cells than in their cisplatin-sensitive counterparts. Findings: Silencing of PTGER3 via siRNA in cancer cells was associated with decreased cell growth and less invasiveness, as well as cell-cycle arrest and increased apoptosis, mediated through the Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. Furthermore, sustained PTGER3 silencing with multistage vector and liposomal 2’-F-phosphorodithioate-siRNA–mediated silencing of PTGER3 combined with cisplatin resulted in robust antitumor effects in cisplatin-resistant ovarian cancer models. Interpretation: These findings identify PTGER3 as a potential therapeutic target in chemoresistant ovarian cancers expressing high levels of this oncogenic protein. Fund: National Institutes of Health/National Cancer Institute, USA.

AB - Background: Inflammatory mediator prostaglandin E2–prostaglandin E2 receptor EP3 (PTGER3) signaling is critical for tumor-associated angiogenesis, tumor growth, and chemoresistance. However, the mechanism underlying these effects in ovarian cancer is not known. Methods: An association between higher tumoral expression of PTGER3 and shorter patient survival in the ovarian cancer dataset of The Cancer Genome Atlas prompted investigation of the antitumor effects of PTGER3 downmodulation. PTGER3 mRNA and protein levels were higher in cisplatin-resistant ovarian cancer cells than in their cisplatin-sensitive counterparts. Findings: Silencing of PTGER3 via siRNA in cancer cells was associated with decreased cell growth and less invasiveness, as well as cell-cycle arrest and increased apoptosis, mediated through the Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. Furthermore, sustained PTGER3 silencing with multistage vector and liposomal 2’-F-phosphorodithioate-siRNA–mediated silencing of PTGER3 combined with cisplatin resulted in robust antitumor effects in cisplatin-resistant ovarian cancer models. Interpretation: These findings identify PTGER3 as a potential therapeutic target in chemoresistant ovarian cancers expressing high levels of this oncogenic protein. Fund: National Institutes of Health/National Cancer Institute, USA.

KW - CFTR

KW - Chemically modified siRNA

KW - Cisplatin resistance

KW - ELK1

KW - ETS1

KW - Ovarian cancer

KW - PTGER3

KW - RNA interference

UR - http://www.scopus.com/inward/record.url?scp=85059851379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059851379&partnerID=8YFLogxK

U2 - 10.1016/j.ebiom.2018.11.045

DO - 10.1016/j.ebiom.2018.11.045

M3 - Article

VL - 40

SP - 290

EP - 304

JO - EBioMedicine

JF - EBioMedicine

SN - 2352-3964

ER -